ChemoCentryx's earnings call highlighted promising clinical trial data, particularly for Avacopan in ANCA-associated vasculitis (ADVOCATE trial).  Management expressed confidence in achieving positive results, suggesting a potential for a significant impact on the stock price due to the significant unmet need and the potential for a new standard of care.  The company's strong financial position and multiple ongoing trials further bolster the positive outlook.
[2]
